Editorial: Drug cost and the rules of engagement
This article was originally published in Scrip
As I write, European Parliamentarians are limbering up for a debate on access to medicines in the EU. The Greens/European Free Alliance are arguing that it is a scandal not only that some patients cannot afford life-saving medicines because of their "astronomical prices", but also that the European Commission and EU governments are failing to act by "tackling the issue of monopolies and abuse of market position". This viewpoint is expected to set the tone for a debate in which the pharma industry is the villain.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.